ADVANTAGE: Advanced discovery of visceral analgesics by neuroimmune targets and the genetics of extreme human phenotype, a study protocol
Marco Vinicio Alban-Paccha, Nicholas Shenker, Jimena Teran-Perez, Andrew W Horne, George G Malliaras, Christopher Geoffrey Woods, on behalf of the ADVANTAGE Consortium · 2026
Read ADVANTAGE: Advanced discovery of visceral analgesics by neuroimmune targets and the genetics of extreme human phenotype, a study protocol by Marco Vinicio Alban-Paccha, Nicholas Shenker, Jimena Teran-Perez, Andrew W Horne, George G Malliaras, Christopher Geoffrey Woods, on behalf of the ADVANTAGE Consortium (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0350169.txt.
Description
Marco Vinicio Alban-Paccha and colleagues lay out the protocol for ADVANTAGE, a study hunting for new painkillers for chronic gut and pelvic pain by studying extreme cases. More than one in five adults live with such visceral pain, yet its mechanisms are poorly understood. The project recruits three groups: people with extreme pain, people who strangely feel almost none, and healthy volunteers.
Participants give genetic samples and immune profiles, map their pain, wear sensors, and log daily pain in a phone app. Conditions range from endometriosis to chronic pancreatitis. Comparing the extremes can reveal protective and risk factors invisible in average patients. This paper is the plan, registered before results, for the consortium's search for drug targets.
Catalog record
| CREATOR | Marco Vinicio Alban-Paccha, Nicholas Shenker, Jimena Teran-Perez, Andrew W Horne, George G Malliaras, Christopher Geoffrey Woods, on behalf of the ADVANTAGE Consortium |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55720 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |